Shaktilmaran It also includes a demand of Rs. Pending disposal of the matter, the management considers the impact as unascertainable. The Company has also issued redeemable non-convertible debentures which are listed for trading on the NSE in India. The options vests evenly over a period of three years from the date of grant.
|Published (Last):||1 August 2010|
|PDF File Size:||17.22 Mb|
|ePub File Size:||13.52 Mb|
|Price:||Free* [*Free Regsitration Required]|
To receive, consider and adopt the Balance Sheet as at 31st March, and the Profit and Loss Account for the year ended on that date and the Reports of the Directors and Auditors thereon.
To declare a final dividend for the financial year ended 31st March, To appoint a Director in place of Shri Rajendra V. Gogri, who is liable to retire by rotation and being eligible, offers himself for re-appointment.
To appoint a Director in place of Shri Ramdas M. Gandhi, who is liable to retire by rotation and being eligible, offers himself for re-appointment. To appoint a Director in place of Shri Harit P. Shah, who is liable to retire by rotation and being eligible, offers himself for re-appointment.
To appoint a Director in place of Shri Krishnacharya G. Akamanchi, who is liable to retire by rotation and being eligible, offers himself for re-appointment. To appoint Auditors and fix their remuneration.
Shah be and is hereby appointed as a Director of the Company. Registered Office: Plot No. Thane Aarti Drugs Limited Annual Report 3. Corporate Members are requested to send a duly certified copy of the Board resolution authorizing their representatives to attend and vote at the meeting. All documents referred to in the accompanying notice and explanatory statement are open for inspection at the registered office of the Company on all working days except Saturdays, between Sharepro Services India Private Limited, immediately of any change in their address and bank details.
Members holding shares in dematerialized form are requested to intimate all changes with respect to their address, bank details, mandate etc. These changes will then be automatically reflected in the Companys records. This will help the Company to provide efficient and better service to the Members. Sharepro Services India Private Limited.
Blank forms will be supplied by the Company on request. Members holding shares in demat form may contact their respective Depository Participants for recording of nomination.
Members who have not encashed their final dividend warrants for the year or thereafter, are requested to write to the Company or the RTA.
It may be noted that once the unclaimed dividend is transferred to the IEPF as above, no claim shall lie with the Company in respect of such amount. The Company has transferred unclaimed amounts of dividends declared for the year and interim dividend for the year to the Investor Education and Protection Fund as required under Sections A and C of the Companies Act, Gogri Shri Ramdas M.
Gandhi He is an Independent Director of the Company. Crystal Millennium Realtors Pvt. Shah Com Shri Krishnacharya G. Akamanchi Com, FCA Experience and expertise He has experience of over in specific functional areas 15 years handling commercial functions encompassing Sales, Purchases and Exports.
He looks after Local Sales and Export as well. Institute of Chemical Technology, Mumbai. He has vast experience in handling industrial projects for solving the process chemistry and process technology problems and also development of new technologies. Since he has been providing consultancy for Process Technology Development, Process Chemistry Development, Project Evaluation, and Diversification into emerging areas to many industries. To support this green initiative of the Government in full measure, members who have not registered their e-mail addresses, so far, are requested to register their e-mail addresses, in respect of electronic holdings with the Depository through their concerned Depository Participants.
Shah, Chartered Accountant with over 25 years experience was appointed as an Independent Director by the Board of Directors on 4th November, pursuant to Section of the Companies Act, He holds office up to the date of ensuing Annual General Meeting.
The Company has received a notice in writing from a member proposing his candidature for the office of Director of the Company under section of the Companies Act, , alongwith the requisite amount of deposit. Your Directors recommend the resolution at Item No. Except Mr. Navin C. Shah, none of the Directors is, in any way, concerned or interested in the said resolution. Your Directors have recommended a final Dividend of Rs. Total cash outflow on account of dividend payment including dividend tax will be Rs.
The Company has achieved Export Turnover of Rs. There are no material departures from the applicable accounting standards; ii the Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company at the end of the financial year and of the profit of the Company for that year; iii the Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities; iv the Directors have prepared Annual Accounts on a going concern basis.
The Company will make available the Annual Accounts of the subsidiary company and the related detailed information to any member of the Company who may be interested in obtaining the same. The annual accounts of the subsidiary will also be kept open for inspection at the Registered Office of the Company as well as at the head office of the subsidiary company. The Consolidated Financial Statements presented by the Company include the financial results of its subsidiary company.
Rajendra V. Gogri , Mr. Ramdas M. Gandhi, Mr. Harit P. Shah and Prof. Krishnacharya G. Akamanchi retire by rotation and being eligible, offer themselves for re-appointment.
However, as per the provisions of the section 1 b iv of the Companies Act,, this Report is sent to the shareholders excluding the said information. Any shareholder interested in obtaining such particulars may write to the Company Secretary at the Registered Office of the Company. Members are requested to appoint Auditors and to fix their remuneration. As regards comment of the Auditors at clause xv of the Annexure to their report, it is clarified that short term funds were applied to fund part of ongoing capital expenditure which was to be funded by internal accruals which got affected to some extent due to shut down of certain APIs plants for about one and half month to align these existing facilities for expanded capacity and under performance for major part of the year of Sarigam plants due to environmental issues in the whole Sarigam Industrial Area.
The mismatch in application of funds as aforesaid is temporary in nature since expansion made is expected to generate internal accruals in the current year. Girish S. Maniar, Cost Accountant, was re-appointed as the cost auditor for the financial year and the report thereof will be submitted to the Central Government in due course. The relations between the management and the staff remained very cordial and satisfactory throughout the year under review.
We also thank all our associated customers and suppliers who are always co-operative. We also express our sincere thanks to Bankers, Financial Institutions and the Shareholders for their continued support. However, in future more growth potential lies within emerging markets, where major world population resides. Increased per capita income of this population will give them enough spending power to satisfy their needs for treatment of chronic lifestyle diseases more typically found in developed countries.
The Indian Pharmaceutical industry is now the third largest producer of drugs and pharmaceutical in the world. India is also the third-largest market in the world in terms of volume and fourteenth in terms of value. By , total Indian pharmaceutical market would be almost equally be contributed by bulk drug exports, formulation exports and domestic formulations. Business Strategy Domestic Market and Trends: Aarti Drugs Limited ADL is constantly gearing up to cater the demand with a diversified products basket of drugs in the Anti-diabetic, Anti-infective, Anti-hypertensive and Cardio vascular therapeutic groups.
ADL expects to increase its market share in the Antibiotic segment, which is growing fast due to penetration of health services in rural areas of the country.
To cope up with the above demand ADL has already expanded its existing product-lines capacities. There is also a shift in demand from drugs treating hygiene related diseases to drugs treating lifestyle related diseases in the urban sector.
ADL has already upgraded its facilities to meet high-standards, as lot of Indian formulators have started exporting ready-formulations to regulated markets. COS approvals and supplier registrations for ADLs several existing products will be on going process. We are now looking to increase our hold on Asian markets as well. ADL will continue to cater global pharmaceutical markets through following channels: Contract Manufacturing Direct Exports Increasing its share of direct exports to regulated and nonregulated markets.
Bigger market share will automatically help us to be competitive in market due to lower overheads. In addition to the existing exports to 86 countries worldwide, ADL is developing business in new geographies as well. Our scientists are responsible for developing technology, non-infringing route of synthesis, scale up and its transfer to manufacturing location for commercialization.
They are actively working not only on bulk drugs in therapeutic areas like Anti-histamine, Antibiotics, Anti-Anginal, Antitussive, Anticonvulsant, Anti-diabetics, Anti-depressant, Anti-fungal, Anti-hypertensive and Antipsychotic but also on specialty chemicals for non-API related applications. The Company has USFDA approved plants that will help to increase share in regulated market, for recently off-patent gone drugs or are scheduled to be off patent soon.
Entry in regulated markets will be steady and systematic process, as we will have to go through different stages of products approvals. Weakness, Risk and Concerns Crude oil prices have gone up and are expected to continue to grow due to perennial need and limited supply. ADL is looking into newer and greener technologies like briquette fired boilers etc. However, ADL was able to cope up with these pressures due to strong operational efficiency and increased market share of its products.
Exchange rate of rupee against US dollar has been relatively steady last year. Volatility of US dollar against rupee is always a concern for us. Part of ADLs foreign exchange risk is automatically hedged because of its imports that partially balance its exports. Internal Control System and their Adequacy The Company has sound and adequate internal control systems commensurate with its size and nature of business.
Annual Report 2010-11
Annual Reports & Presentations